147 related articles for article (PubMed ID: 14734445)
1. Reducing the immune response to immunotoxin.
Frankel AE
Clin Cancer Res; 2004 Jan; 10(1 Pt 1):13-5. PubMed ID: 14734445
[No Abstract] [Full Text] [Related]
2. Pretreatment with rituximab does not inhibit the human immune response against the immunogenic protein LMB-1.
Hassan R; Williams-Gould J; Watson T; Pai-Scherf L; Pastan I
Clin Cancer Res; 2004 Jan; 10(1 Pt 1):16-8. PubMed ID: 14734446
[TBL] [Abstract][Full Text] [Related]
3. The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma.
Flavell DJ; Warnes SL; Bryson CJ; Field SA; Noss AL; Packham G; Flavell SU
Br J Haematol; 2006 Jul; 134(2):157-70. PubMed ID: 16771848
[TBL] [Abstract][Full Text] [Related]
4. [Therapeutic monoclonal antibodies in onco-hematology].
Cartron G; Rossi JF
Med Sci (Paris); 2009 Dec; 25(12):1085-9. PubMed ID: 20035683
[TBL] [Abstract][Full Text] [Related]
5. [Monoclonal antibody therapy targeting surface antigens of leukemic cells].
Meng FY; Fu YB
Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):441-3. PubMed ID: 15854546
[No Abstract] [Full Text] [Related]
6. Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia.
Robak T
Future Oncol; 2013 Jan; 9(1):69-91. PubMed ID: 23252565
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibody therapy for central nervous system lymphomas: an emerging treatment paradigm.
Wong ET
Expert Opin Pharmacother; 2005 Jun; 6(7):1107-14. PubMed ID: 15957965
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab.
Bologna L; Gotti E; Manganini M; Rambaldi A; Intermesoli T; Introna M; Golay J
J Immunol; 2011 Mar; 186(6):3762-9. PubMed ID: 21296976
[TBL] [Abstract][Full Text] [Related]
9. The future of CD20 monoclonal antibody therapy in B-cell malignancies.
Czuczman MS; Gregory SA
Leuk Lymphoma; 2010 Jun; 51(6):983-94. PubMed ID: 20367564
[TBL] [Abstract][Full Text] [Related]
10. [Preparation of the immunotoxin 2E8-norcantharidin and its targeting killing effect in vitro].
Li LX; Tang YM; Zhang HZ; Shen HQ; Qian BQ; Luo CF
Zhonghua Er Ke Za Zhi; 2008 Jul; 46(7):493-7. PubMed ID: 19099803
[TBL] [Abstract][Full Text] [Related]
11. Systemic immunotoxin therapy of cancer: advances and prospects.
Wawrzynczak EJ
Br J Cancer; 1991 Oct; 64(4):624-30. PubMed ID: 1911210
[No Abstract] [Full Text] [Related]
12. Monoclonal antibodies in the treatment of chronic lymphoid leukemias.
Robak T
Leuk Lymphoma; 2004 Feb; 45(2):205-19. PubMed ID: 15101704
[TBL] [Abstract][Full Text] [Related]
13. Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies.
Ma D; McDevitt MR; Barendswaard E; Lai L; Curcio MJ; Pellegrini V; Brechbiel MW; Scheinberg DA
Leukemia; 2002 Jan; 16(1):60-6. PubMed ID: 11840264
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibodies in adult acute lymphoblastic leukemia.
Kantarjian H
Hematology; 2012 Apr; 17 Suppl 1():S52-4. PubMed ID: 22507779
[TBL] [Abstract][Full Text] [Related]
15. The clinical and biological role of CD20 membrane antigen modulation under immunotherapy with anti-CD20 monoclonal antibody rituximab in lymphoprolipherative neoplastic disorders.
Musto P; D'Auria F
Expert Opin Biol Ther; 2011 May; 11(5):551-7. PubMed ID: 21385115
[TBL] [Abstract][Full Text] [Related]
16. The Tumor Microenvironment Regulates CD19 and CD20 Immunotherapy for Lymphoma.
Lykken JM; Tedder TF
Cancer J; 2015; 21(4):351-6. PubMed ID: 26222089
[TBL] [Abstract][Full Text] [Related]
17. [Anti-CD20 antibody for the treatment of systemic autoimmune diseases].
Tanaka Y
Nihon Rinsho Meneki Gakkai Kaishi; 2004 Feb; 27(1):28-33. PubMed ID: 15045813
[No Abstract] [Full Text] [Related]
18. Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs.
Sapra P; Allen TM
Cancer Res; 2002 Dec; 62(24):7190-4. PubMed ID: 12499256
[TBL] [Abstract][Full Text] [Related]
19. Rapid response of treatment-resistant pemphigus foliaceus to the anti-CD20 antibody rituximab.
Goebeler M; Herzog S; Bröcker EB; Zillikens D
Br J Dermatol; 2003 Oct; 149(4):899-901. PubMed ID: 14616397
[No Abstract] [Full Text] [Related]
20. [Anti-CD20 antibody therapy for inflammatory immune diseases].
Tanaka Y
Nihon Naika Gakkai Zasshi; 2006 Sep; 95(9):1801-6. PubMed ID: 17037318
[No Abstract] [Full Text] [Related]
[Next] [New Search]
